Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 1, 2007

View Archived Issues

The novel Spigelmer mNOX-E36 shows promise in mouse models of lupus

Snapshots: Recent clinical results in COPD

Similar efficacy seen with ibandronate and alendronate in postmenopausal osteoporosis

Agenix recruits first patient for phase II study of ThromboView for PE detection

ThromboGenics completes patient enrollment in MIVI IIT trial

Update on Curis' CUDC-101 and targeted cancer drug development platform

Labopharm requests meeting with FDA regarding NDA for once-daily tramadol

MerLion begins phase I trials of finafloxacin for H. pylori

Positive results for Orexigen's two phase I trials of naltrexone SR

Patient dosing begins in DiObex's phase IIb trial of type 2 diabetes drug

Keryx sells Zerenex licensing to JT and Torii for development and marketing in Japan

Positive preliminary results from Arena's phase II trial of APD-125 for insomnia

Tocosol Paclitaxel does not meet primary endpoint in study in metastatic breast cancer

ISTA licenses North American rights to nasal bepotastine from Tanabe Seiyaku

PMDA recommends additional trial for Chugai's new Epogin injection indication

Taisho and BCI sign license agreement for novel compounds for CNS indications

U.S. awards USD 15 million to GeoVax's HIV/AIDS vaccine program

EMEA recommends amendment to prescribing information for ESAs in the E.U.

Positive results for Pharmacopeia's phase I confirmation study of PS-433540

Novel class of HIV-1 integrase inhibitors with distinct mechanism of strand transfer inhibition

Antivirulence DltA inhibitors enhance host's innate immunity against Gram-positive infections

Novel tachykinin NK1 receptor antagonists emerge from Tanabe Seiyaku R&D

Novel antiinfective agents disclosed in recent patent literature

AstraZeneca prepares and tests novel beta2-adrenoceptor agonists

Novartis' Galvus approved in combination with oral antidiabetes medicines in Europe

Vanda submits NDA to FDA for iloperidone for schizophrenia

CV Therapeutics submits sNDA to FDA to expand Ranexa label

FDA approves Daiichi's once-daily Azor for hypertension

Update on Pfizer's study of CCR5 antagonist Selzentry for HIV

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...